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Abstract 
Background: Norepinephrine is a key drug for treating shock but has a short half‑life that requires continuous intra‑
venous administration to maintain the constant plasma concentration needed to obtain a stable blood pressure. The 
small volume of the syringes used in power infusion pumps requires frequent changeovers, which can lead to nor‑
epinephrine flow interruptions responsible for hemodynamic instability. Changeovers from the nearly empty to the 
full syringe can be performed manually using the quick change technique (QC) or automatically using smart infusion 
pumps (SIP) that link two syringes. The purpose of our study was to evaluate the hypothesis that, compared to QC, SIP 
for norepinephrine changeovers was associated with less hemodynamic instability.
Methods: After information of the patient or next of kin, patients receiving norepinephrine for shock were allocated 
to QC or SIP changeovers. QC changeovers were performed by a nurse, who started a new loaded pump when the 
previous syringe was nearly empty. SIP changeovers were managed automatically by SIP workstations. The primary 
outcome was the proportion of changeovers followed by a ≥20 % drop in mean arterial pressure (MAP).
Results: 411 changeovers were performed, 193 in the 18 patients allocated to QC and 218 in the 32 patients allo‑
cated to SIP. Baseline patient characteristics were similar in both groups. The proportion of changeovers followed by 
an MAP drop ≥20 % was 12.4 % (24/193) with QC and 5.5 % (12/218) with SIP (P = 0.01). By multivariate analysis, two 
factors were independently associated with a significantly decreased risk of ≥20 % MAP drops during changeovers, 
namely, SIP (odds ratio, 0.47; 95 % confidence interval, 0.22–0.98) and norepinephrine dosage >0.5 μg/kg/min (odds 
ratio, 0.39; 95 % confidence interval, 0.19–0.81).
Conclusions: The risk of MAP drops ≥20 % during changeovers can be significantly diminished using SIPs instead of 
the QC method.
Trial registration: Clinicaltrial.gov NCT 01127152
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Background
The management of hemodynamic failure, a key issue in 
intensive care, requires close and continuous monitoring 
and treatment. Vasoactive drugs are used to reverse vaso-
plegia and/or to treat heart failure in patients with per-
sistent hemodynamic instability after volume repletion to 
correct hypovolemia [1–3]. Norepinephrine is currently 
the most widely used drug to treat vasoplegia, because 
of its potent and selective effects on vascular alpha 
receptors [4]. Similar to all other vasoconstrictors, nor-
epinephrine has a short half-life. These features require 
intravenous administration at a constant flow rate, which 
can be achieved using a high-precision power infusion 
pump [5, 6].
The syringes used with power infusion pumps are 
small and must therefore be changed frequently. The 
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changeover between vasoactive drug infusion pumps 
(CVIP) can induce a brief change in the drug flow rate 
manifesting as hemodynamic instability [7]. Various 
methods for performing manual or automatic changeo-
vers have been developed to prevent episodes of hemo-
dynamic instability [6, 8]. In the quick change method 
(QC), a full syringe is loaded into a new pump then con-
nected to the three-way stopcock, which is turned to 
open the new and close the old infusion. This new primed 
line is set at the same flow rate as the running pump. QC 
has been proven simple and effective for manual CVIP [7, 
9, 10] but does not completely eliminate the risk of insta-
bility. In addition, QC generates considerable work and 
stress for the nurse.
Smart infusion pumps (SIP) linking two syringes have 
been developed to allow automatic CVIP without chang-
ing the flow rate [11]. The SIP software has a number of 
capabilities, including a relay feature that can link a full 
syringe and a nearly empty syringe, thereby limiting flow 
rate interruptions during CVIP while decreasing the 
need for nurse interventions. Compared to manual CVIP, 
automated CVIP using an SIP may therefore minimize 
episodes of hemodynamic instability. A before–after 
study showed reduced rates of hemodynamic incidents 
and decreased nurse workload with SIP compared to QC 
[12]. However, the available data are scant, and no rand-
omized trials or guidelines are available.
The purpose of this prospective controlled trial was 
to investigate whether using a SIP for norepinephrine 




This prospective controlled trial was conducted from 
June 2009 to February 2011 in the 18-bed adult medical-
surgical intensive care unit (ICU) of the District Hospital 
Centre in La Roche-sur-Yon, France. The study protocol 
was approved by the appropriate ethics committee (Com-
ité de Protection des Personnes de Poitiers) on April 15, 
2009. According to French law, because the strategies 
used in both study groups are considered standard care, 
there was no requirement for signed informed consent. 
However, information of the patient or next of kin was 
required before inclusion in the study. The patient or next 
of kin could decline participation in the study at any time 
after being informed or included.
Patients
Adults (age  >  18  years) admitted to the ICU and given 
norepinephrine to treat shock were eligible for inclu-
sion. Exclusion criteria were moribund status, pregnancy 
or breastfeeding, infusion of another medication via the 
central venous port used for norepinephrine adminis-
tration, absence of healthcare insurance, refusal of the 
patient or next of kin to participate in the study, pheo-
chromocytoma, and carcinoid tumor.
Allocation
Eligible patients were informed about the study then 
enrolled by study nurses, who randomly allocated them 
in a 1:1 ratio to the QC or SIP method for CVIP, as 
described below. The random allocation sequence was 
generated by the clinical research unit of the La Roche 
Sur Yon District Hospital, using Random© (Inserm, Paris, 
France). No stratification was performed. Implementa-
tion of the sequence was by opaque sealed envelopes to 
ensure concealment.
Norepinephrine administration
Infusion lines and norepinephrine syringes were pre-
pared according to the written protocol of the unit. The 
infusion lines were similar in both groups (Fig.  1). All 
devices used for the study were those used habitually 
in the unit. All ICU nurses were trained in using power 
infusion pumps, setting up infusion lines, and preparing 
norepinephrine syringes. They attended a training pro-
gram specifically designed to ensure optimal quality and 
standardization of QC and SIP changeovers. These train-
ing programs were delivered by three highly experienced 
ICU nurses, who were in charge of bedside nurse training 
in our unit. Written standardized protocols for QC and 
SIP changeovers were developed, and the ability of each 
ICU nurse to follow them successfully was checked by 
the training nurses.
All study patients received continuous norepineph-
rine via a dedicated infusion line (BD Medical, Le Pont 
de Clais, France) connected to the proximal lumen of a 
multilumen central venous catheter (Arrow, Kingston, 
UK). Each Luer-Lock 60-mL syringe was loaded with an 
amount of norepinephrine, in mg, equal to the patient’s 
body weight multiplied by 0.3; water for intravenous 
injection (Renaudin, Itxassou, France) was then added to 
obtain a total volume of 50 mL. The NE ampoules used 
in our unit to prepare the syringes contained 8  mg of 
NE. When the calculated NE requirement was between 
23 and 25  mg, the nurses rounded to 24  mg (three 
ampoules) to increase the efficiency and speed of prepa-
ration at the bedside. The infusion rate in μg/kg/min was 
equal to 1/10 of the injection speed of the power infusion 
pump. Changeovers were performed when the syringe 
contained 5 mL or less; finally, as a safeguard, the electric 
infusion pump triggered a buzzer when less than 2  mL 
of the norepinephrine solution was left in the syringe. In 
both groups, a 5 % dextrose carrier of the norepinephrine 
infusion was used [13]. It was infused by gravity with a 
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flow rate regulator (Fig. 1). The flow was set at 5 mL/h for 
all patients and checked regularly by the nurse at the bed-
side [14].
Changeovers in the QC group
Orchestra® power pumps were used (Fresenius Kabi, 
Bad Homburg, Germany). The patient’s nurse prepared a 
new syringe with the same concentration of norepineph-
rine, connected it to a line and to a new power pump set 
at the same flow rate as the running pump, primed the 
line using the bolus function of the pump until a drop of 
norepinephrine solution was visible at the tip of the line 
(thereby minimizing the start-up time of the new infu-
sion), then connected the line to the three-way stop-
cock. When the previous syringe contained 5 mL or less 
of norepinephrine solution, the nurse turned the stop-
cock to stop the old infusion and start the new infusion. 
Throughout this procedure, the patient was monitored 
closely by the nurse, who remained at the bedside.
Changeovers in the SIP group
The Orchestra® Base Intensive SIP workstation (Fre-
senius Kabi) was used. This device can manage up to 
six power infusion pumps and can perform automated 
changeovers by driving one syringe after the other at the 
same flow rate. The nurse presses the changeover but-
ton on the workstation, causing the display to divide into 
two windows, one for each syringe. The nurse then loads 
the new syringe containing norepinephrine solution in 
the same concentration as the running syringe. The new 
syringe is primed using the bolus function of the pump 
until a drop of norepinephrine solution appears at the 
end of the new line. Then, the new infusion line is con-
nected to the three-way stopcock, which is then opened 
to both lines. After validation by the nurse, the worksta-
tion display shows the word “relay”, indicating that the 
device is ready to perform the changeover. When the 
relay occurs, a buzzer sounds to let the nurse know that 
blood pressure should be monitored.
Data collection and follow‑up
We collected the following baseline patients character-
istics: age, gender, weight, body mass index, admission 
diagnosis, Simplified Acute Physiology Score II (SAPS II 
score; range from 0, lowest level of critical illness to 163, 
most severe level of critical illness) [15], cause of shock, 
Sepsis-related Organ Failure Assessment score (SOFA 
score; range from 0, no organ failure to 24, highest level 
of multiple-organ failure) [16], mechanical ventilation, 
ICU length of stay, and ICU and hospital mortality. For 
each CVIP, we collected the SOFA score, the norepineph-
rine dose (μg/kg/min) and concentration (mg/50  mL), 
blood pressure, and heart rate (HR). Noninvasive blood 
pressure monitoring has been proven accurate in detect-
ing MAP drops [17], and invasive monitoring via an 
arterial catheter was therefore not required by the study 
Fig. 1 Infusion line setup. a Multilumen central venous catheter (Arrow, Kingston, UK); b infusion line (BD Medical, Le Pont de Clais, France) con‑
nected to the proximal lumen of the central venous catheter; c perfusion ramp with a three‑way stopcock (Vygon, Ecouen, France); d anti‑reflux 
valve (Arrow, Kington, UK); e infusion rate control (CAIR LGL, Lissieu, France); f infusion pump; g Dextrose 5 % infusion set (B. Braun, Boulogne Bil‑
lancourt, France)
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protocol. Blood pressure was monitored continuously if 
the patient had an arterial catheter for another reason 
(Arrow, Kingston, UK) and at 1-min intervals using an 
automatic sphygmomanometer (Philips, DA Best, Neth-
erlands) with an appropriately sized cuff otherwise. Max-
imal and minimal values of HR and MAP were recorded 
every 5 min over a period ranging from 15 min before to 
15 min after each changeover.
Study outcome
The primary outcome was the proportion of changeo-
vers followed by an MAP drop ≥20  % within 15  min 
after the changeover. The 15 min were counted starting 
at the stopcock turn in the QC group and the buzzer in 
the SIP group. Secondary outcomes were the propor-
tions of changeovers followed by a ≥15 % MAP drop, a 
≥10  % MAP drop, severe hypotension defined as MAP 
<50 mmHg, and a ≥20 % HR change in either direction, 
within 15 min after the changeover.
Sample size
We expected an MAP drop ≥20  % to occur within 
15  min after 20  % of QC procedures [7]. To detect a 
10 % decrease in the primary outcome in the SIP group, 
with α set at 0.05 and 80 % power, 200 changeovers were 
required in each group. All changeovers in each patient 
were included in the study. Patients on norepinephrine 
therapy usually require about 10 changeovers in all [7]. 
Therefore, about 40 patients in all (20 per group) were 
required. Because some patients require fewer than 
10 changeovers and missing data may occur for some 
changeovers (e.g., those performed on an emergency 
basis), we planned to include 50 patients in all. The num-
ber of relays was checked during the enrollment phase 
of the study. After inclusion of 36 patients (18 in each 
group), 193 relays were available for analysis in the Quick 
Change Method compared to only 141 in the Smart Infu-
sion Pump group. At this point, we decided to include all 
subsequent patients in the Smart Infusion Pump group 
until the required number of changeovers was reached.
Statistical analysis
Quantitative data were described as means (±standard 
deviation) or medians (25th–75th quartiles) and com-
pared between changeover groups using the Student 
or Wilcoxon–Mann–Whitney tests, as appropriate. 
Qualitative data were described as n (%) and compared 
using the Pearson Chi-square test or Fisher exact test as 
appropriate.
A mixed-effect logistic regression model was fitted 
to assess factors associated with the primary outcome 
(≥20 % MAP drop within 15 min after the changeover). 
This model took the hierarchical  structure  of the data 
into account. We used a random-intercept logistic model 
with changeovers (level 1) nested in patients (level 2). 
Potential confounders related to changeover character-
istics were tested. Potential confounders were identified 
according to the results of the univariate analysis and a 
previous study [12]. Covariates associated with P values 
<0.10 by univariate analysis were entered into the multi-
variate model. Norepinephrine concentration and dose, 
SOFA score, and age were forced into the final multivari-
ate model. Odds ratios (ORs) and their 95 % confidence 
intervals (95  % CIs) were estimated. The same method 
was used to analyze ≥20 % HR variations and other sec-
ondary outcomes.
All comparisons were two-sided, and P values <0.05 
were considered significant. The data were analyzed 
using Stata statistical software version 13.0 (StataCorp 
LP, College Station, TX, USA).
Results
The 50 included patients had 411 changeovers, 193 in the 
18 patients allocated to QC and 218 in the 32 patients 
allocated to SIP (Fig. 2). The median number of change-
overs per patient was 6 [3–12] in the QC group and 3 
[1–11] in the SIP group (P  =  0.07). All patients had at 
least 1 changeover. The only patient characteristic that 
differed significantly between the two groups was ICU 
stay length, which was longer in the QC group (Table 1). 
Table 2 compares the baseline characteristics in the two 
changeover groups; the norepinephrine dose and HR 
were significantly higher in the SIP group than in the QC 
group.
Primary outcome
MAP dropped by ≥20 % in 24/193 (12.4 %) QC changeo-
vers and 12/218 (5.5 %) SIP changeovers (P = 0.01). Mul-
tivariate analysis identified two factors independently 
associated with a significant decrease in the risk of ≥20 % 
MAP drops, namely, SIP (OR, 0.47; 95 % CI, 0.22–0.98) 
and norepinephrine dose >0.5 μg/kg/min (OR, 0.39; 95 % 
CI, 0.19–0.81) (Table 3).
Secondary outcomes
Overall, changeovers were associated with a significant 
MAP increase within the first 5  min, in both groups 
(QC group, from 78 ± 14 to 80 ± 14 mmHg, P = 0.03; 
SIP group, from 77 ± 13 to 78 ± 14 mmHg, P = 0.004) 
(Fig.  3). These increases were not significantly different 
between the two groups (P =  0.22). MAP increased by 
more than 20 % in a single QC patient and none of the 
SIP patients.
MAP drops ≥15  % occurred within 15  min after 40 
(20.7  %) QC changeovers and 21 (9.6  %) SIP changeo-
vers (P  =  0.002). Similarly, MAP drops ≥10  % were 
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significantly more common with QC than with SIP 
(34.2 vs. 24.3 %, P = 0.03). However, severe hypotension 
(MAP  <  50  mmHg) occurred in similar proportions of 
patients in the two groups (4.7 % with QC and 4.1 % with 
SIP, P = 0.79).
HR changes ≥20  % occurred within 15  min after 15 
(7.8  %) changeovers in the QC group (10 increases and 
5 decreases) and 6 (2.8 %) changeovers in the SIP group 
(5 increases and 1 decrease) (P =  0.03). By multivariate 
analysis, the changeover method was not independently 
associated with HR variations (Table 4).
Discussion
We report the first prospective controlled trial designed 
to compare automated norepinephrine syringe changeo-
vers using an SIP to manual changeovers using QC, in 
critically ill adults with shock. Our main finding is that 
SIP changeovers were associated with lower rates of 
hypotension than changeovers managed manually by the 
nurse using the QC technique.
Norepinephrine syringe changeovers are among the 
most important and stressful procedures required by the 
management of shock. There is a risk of decreased drug 
delivery during the changeovers [6, 8], with hypotension 
and clinical deterioration. Several methods have been 
developed to shorten the changeover period, thereby 
limiting the risks to the patient. However, few studies of 
these methods have been published. Manual changeover 
methods include the QC and the double infusion pump 
(DIP) technique. With both methods, the nearly empty 
syringe and the new full syringe, set at the same flow rate, 
are connected to the catecholamine line of the central 
286 patients assessed for eligibility Excluded  (n=236) 
– Inclusion criteria not met (n=195) 
– Concomitant administration of other 
drug via the CVC (n=69) 
– Dying patient (n=38) 
– Weaning off norepinephrine (n=88) 
– Included in another study (n=27) 
– Other reasons (n=14) 
218 changeovers analyzed 
Lost to follow-up (n=0)
Intervention discontinued (n=0)
32 patients allocated to Smart Infusion Pump
had 218 changeovers. 
All patients received the allocated intervention. 
50 patients allocated 
Lost to follow-up (n=0)
Intervention discontinued (n=0)
18 patients allocated to Quick-Change had 193 
changeovers. 
All patients received the allocated intervention. 
193 changeovers analyzed 
Fig. 2 Flowchart
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venous catheter via a three-way stopcock, which is used 
to close the running infusion and open the new infusion 
at the same time. With QC, a brief interruption in the 
drug infusion may occur if the new line is not perfectly 
primed and/or the old syringe empties before the stop-
cock is turned to the new syringe and/or a delay occurs 
Table 1 Patient characteristics
SAPS II Simplified Acute Physiology Score, version II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, IQR inter-quartile range
Quick change method (n = 18) Smart infusion pump (n = 32) P value
Age (years), mean ± SD 63.3 ± 13.4 68.1 ± 12.8 0.22
Gender (male), n (%) 14 (77.8 %) 25 (78.1 %) 0.98
Weight (kg), mean ± SD 77.7 ± 14.1 86.5 ± 19.9 0.10
Body mass index (kg/m2), mean ± SD 27.7 ± 5.5 29.9 ± 5.0 0.36
Admission diagnosis, n (%) 0.26
 Cardiac arrest 2 (11.1 %) 3 (9.4 %)
 Circulatory failure 9 (50 %) 9 (28.1 %)
 Acute respiratory failure 3 (16.7 %) 14 (43.8 %)
 Trauma 0 1 (3.1 %)
 Other 4 (22.2 %) 5 (15.6 %)
Surgical patient, n (%) 8 (44.4 %) 8 (25.0 %) 0.16
SAPS II, mean ± SD 64.1 ± 19.3 65.9 ± 18.6 0.75
Method of arterial pressure monitoring 0.72
 Automatic sphygmomanometer 3 (16.7) 8 (25.0)
 Invasive arterial line 15 (83.3) 24 (75.0)
Cause of shock, n (%) 0.78
 Sepsis 14 (77.8 %) 24 (75.0 %)
 Hemorrhage 2 (11.1 %) 2 (6.4 %)
 Other 2 (11.1 %) 5 (16.1 %)
SOFA score at inclusion, mean ± SD 12.5 ± 4.0 11.3 ± 2.7 0.21
Mechanical ventilation, n (%) 17 (94.4 %) 29 (90.6 %) 0.63
ICU length of stay (days), median (IQR) 15 [9–34] 9 [3–25.5] 0.03
ICU mortality, n (%) 5 (27.8 %) 13 (40.6 %) 0.36
Hospital mortality, n (%) 5 (27.8 %) 14 (43.7 %) 0.26
Table 2 Baseline characteristics in the two changeover groups
SOFA Sequential Organ Failure Assessment, NE norepinephrine, IQR inter-quartile range
Quick change method (n = 193) Smart infusion pump (n = 218) P value
Age in years, mean ± SD 64.9 ± 12.2 65.7 ± 15.0 0.71
Male, n (%) 177 (91.7 %) 204 (93.6 %) 0.47
Weight, mean ± SD 78.8 ± 15.5 81.6 ± 18.5 0.84
Body mass index (kg/m2), mean ± SD 26.7 ± 5.7 28.6 ± 4.2 0.13
Cause of shock, n (%) 0.34
 Sepsis 176 (91.2 %) 194 (90.6 %)
 Hemorrhage 10 (5.2 %) 7 (3.3 %)
 Other 7 (3.6 %) 13 (6.1 %)
SOFA score, mean ± SD 13.3 ± 3.1 12.9 ± 3.1 0.2
Mechanical ventilation, n (%) 186 (96.4 %) 215 (98.6) 0.14
Dose of NE, µg/kg/min, median [IQR] 0.6 [0.3–1.2] 0.8 [0.4–2.0] <0.001
Concentration of NE, mg/50 mL, mean ± SD 25.1 ± 6.9 24.8 ± 6.3 0.34
Heart rate at baseline 99.3 ± 22.1 107.2 ± 18.9 <0.001
Mean arterial blood pressure at baseline 78.2 ± 13.8 76.8 ± 13.4 0.31
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while turning the stopcock. Theoretically, none of these 
problems can occur with the DIP method, in which there 
is an overlap between the two syringes with a gradual 
decrease in the flow rate of the old syringe and a com-
mensurate gradual increase in the flow rate of the new 
syringe. However, neither method is well standardized, 
a shortcoming that can result in flow rate variations, 
stress, human error, and hemodynamic instability. Pre-
vious studies found no significant differences in the risk 
of hemodynamic instability between QC and DIP [7, 9, 
10]. Compared to DIP, QC is less time-consuming and 
therefore associated with a lower workload. We con-
sequently chose QC as the comparator to SIP in our 
trial. SIPs were designed to drive syringe pumps and 
changeovers automatically according to specific algo-
rithms to standardize drug delivery and decrease the 
nurse workload, thereby reducing the risk of error and 
improving the quality of care. However, their use remains 
controversial [11]. In some studies, the use of SIPs failed 
to improve drug safety [18, 19], due to the complexity of 
the SIP algorithm and settings. This complexity requires 
specific training of the nurses, which has been shown to 
decrease unwanted hemodynamic events after changeo-
vers [7]. As indicated previously, all the nurses in our unit 
received in depth training and familiarization with both 
changeover methods. In a recent study, the use of an SIP 
for CVIP decreased the frequency of adverse hemody-
namic events compared to QC [12]. However, the non-
randomized before–after design of this study limits the 
interpretation of the results, as effects of time and other 
confounding factors cannot be excluded. Moreover, the 
patients received a variety of vasoactive drugs including 
norepinephrine, epinephrine, and dobutamine, whose 
different effects on α- and β-adrenergic receptors pro-
duce different changes in vascular tone, HR, and myo-
cardial contractility [4] and, therefore, in blood flow and 
blood pressure. Thus, the variations in hemodynamic 
variables observed in this study [12] may be related to the 
changeover, drug effects, or both. In our trial, only nor-
epinephrine was used. Norepinephrine chiefly induces 
vasoconstriction and is considered the vasopressor of 
choice for most critically ill patients with shock [1, 2, 20]. 
Last, in addition to the device or changeover technique, a 
major issue is standardization of the circuit to eliminate 
variations in dead volume, compliance, resistance, and 
flow rate [21]. In our study, the perfusion lines were set 
up in a standardized manner and in the same way in all 
study patients. In the light of these considerations, we 
are confident that the between-group differences in our 
study were ascribable only to the changeover technique.
Table 3 Multivariate analysis to  identify factors indepen-
dently associated with mean arterial pressure (MAP) drops 
≥20 % versus baseline
OR odds ratio, 95 % CI 95 % confidence interval, SIP smart infusion pump, NE 
norepinephrine, SOFA Sequential Organ Failure Assessment
OR [95 % CI] P value
SIP changeover 0.47 [0.22–0.98] 0.04
Concentration of NE 0.95 [0.89–1.02] 0.19
Dose of NE >0.5 μg/kg/min 0.39 [0.19–0.81] 0.01
SOFA score at baseline 1.12 [0.99–1.26] 0.08























Fig. 3 MAP variations before, during, and after norepinephrine changeovers. MAP mean arterial pressure, QC quick change, SIP smart infusion 
pump. Variations in mean values of MAP from 15 min before to 15 min after changeovers in both groups. T0 was just before changeover initiation
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The main finding from our trial is that using an SIP 
for norepinephrine syringe changeovers significantly 
decreased the frequency of MAP drops. This result is 
consistent with the above-mentioned before–after study, 
in which adverse hemodynamic events were also less 
common with SIP than with QC [12]. However, in con-
trast to previous studies, our trial did not include all 
adverse hemodynamic events (MAP drop, MAP eleva-
tion, and HR variation) in the primary endpoint [7, 12]. 
Instead, our primary endpoint was an MAP drop ≥20 %. 
A key goal of shock management is correction of the 
hypotension followed by prevention of further hypoten-
sive episodes potentially responsible for decreased tis-
sue perfusion. Current guidelines on shock recommend 
maintaining MAP at 65 mmHg or higher but do not indi-
cate a maximum MAP value that should not be exceeded 
[2, 3]. Interestingly, as shown in Fig. 3, baseline MAP val-
ues in both groups were above the 65-mmHg minimal 
value indicated in our local shock management protocol. 
Moreover, MAP increased very slightly but significantly 
in both changeover groups. These findings are consistent 
with previous studies and reflect safety behaviors [7, 22] 
manifesting as a reluctance to decrease the norepineph-
rine flow rate even when the MAP target is reached in 
severely ill and unstable ICU patients. During changeo-
vers, the mean MAP increase was also related to the brief 
increase in the norepinephrine flow rate due to the brief 
overlap between the nearly empty and full syringes. There 
is no evidence that moderate MAP increases have delete-
rious effects. A recent large randomized controlled trial 
in patients with septic shock found no significant differ-
ences in outcomes between the group with a high MAP 
target of 85–90  mmHg and the group with a standard 
MAP target of 65–70 mmHg [22]. Another finding from 
our study is that a norepinephrine dose >0.5 μg/kg/min 
was associated with a lower frequency of MAP drops. 
Thus, compared to lower flow rates, a high flow rate of 
norepinephrine protected against the small variations 
that may occur during changeovers. It is thus conceivable 
that maintaining a higher flow rate and using a more 
diluted norepinephrine solution may prevent MAP varia-
tions during changeovers in patients receiving low norep-
inephrine doses. However, higher flow rates may require 
a greater number of changeovers, and thereby increasing 
the risk of hemodynamic incidents. Last, norepinephrine 
has little effect on HR, which was therefore not included 
in our primary outcome. Our results consistently showed 
that the changeover method was not independently asso-
ciated with HR variations.
Limitations of the trial include its single-center design, 
which may restrict the general applicability of the results. 
However, the devices and changeover methods used were 
very similar to those reported previously. Moreover, the 
patient characteristics reflected the overall population 
of patients with shock admitted to nonspecialized ICUs. 
Last, the prospective design strongly limits the risk of 
bias and allows the conclusion that using an SIP is caus-
ally related to a lower frequency of changeover-related 
hypotension. We are thus confident in the reliability and 
general applicability of our data. A second limitation of 
the trial is that, as indicated in the methods section, we 
stopped the randomization process when we found an 
imbalance between the two groups and we subsequently 
included all patients in the SIP group, to obtain similar 
numbers of changeovers in the two groups. We do not 
believe this fact significantly weakens our data, for the 
following reasons: (1) most patients were randomized, 
(2) consecutive patients were included, (3) all patients 
met predefined inclusion criteria, and (4) the multivari-
ate analysis clearly demonstrated that the changeover 
method was independently associated with the occur-
rence of MAP variations. A third limitation is that we did 
not assess nurse workload, as our aim was to focus on 
potential benefits to patients. Although nurse workload 
is subjective, a previous non-randomized study showed a 
decrease in nurse’s workload with SIP use [12]. A fourth 
limitation of our study may lie in the method used to cal-
culate the amount of norepinephrine in the syringe for 
each individual patient. Indeed, doses calculations may 
lead to errors. However, this method has been used for 
many years in our ICU. Thus, all the nurses have consid-
erable experience with it, and we are confident that the 
risk of error was very low. Moreover, although smart 
pumps could calculate doses in µg/kg/min, they were not 
used in the QC group. We therefore used the calculation 
method in both groups to avoid concerns about possible 
differences in norepinephrine concentrations. Last, our 
trial was not designed to assess the potential impact of 
the changeover method on patient outcomes. A far larger 
number of patients would have been required to assess 
possible effects on mortality. However, maintenance of 
hemodynamic stability was associated with improved 
Table 4 Multivariate analysis to  identify factors indepen-
dently associated with  heart rate (HR) changes ≥20  % 
in either direction versus baseline
OR odds ratio, 95 % CI 95 % confidence interval, SIP smart infusion pump, NE 
norepinephrine, SOFA Sequential Organ Failure Assessment
OR [95 % CI] P value
SIP changeover 0.42 [0.12–1.40] 0.16
Concentration of NE 1.01 [0.92–1.11] 0.80
Dose of NE >0.5 μg/kg/min 0.37 [0.13–1.06] 0.06
SOFA score at baseline 1.03 [0.98–1.08] 0.26
Age 1.18 [0.97–1.42] 0.09
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patient outcomes in previous work and is a key goal of 
critical care [23]. Thus, our trial can be viewed as an 
important first step in demonstrating that SIPs improve 
the quality of care. Our results support the conduct of a 
large trial designed to assess the impact of SIP norepi-
nephrine changeovers on patient outcomes.
Conclusion
This prospective controlled trial supports the use of SIPs 
for norepinephrine changeovers in critically ill adults 
with shock. Compared to QC, SIP changeovers are asso-
ciated with improved hemodynamic stability.
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